Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global HIV Associated Lipodystrophy Syndrome Treatment Market by Type (Specific Drug Treatment, Cosmetic Corrective Treatment), By Application (Hospital, Specialist Clinic, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global HIV Associated Lipodystrophy Syndrome Treatment Market by Type (Specific Drug Treatment, Cosmetic Corrective Treatment), By Application (Hospital, Specialist Clinic, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 246853 4200 Medical Care 377 156 Pages 4.7 (45)
                                          

Market Overview:


The global HIV associated lipodystrophy syndrome treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth can be attributed to the increasing prevalence of HIV, growing awareness about HIV associated lipodystrophy syndrome (HALS), and technological advancements in the field of HALS treatment. The specific drug treatment segment is expected to dominate the global HALS treatment market during the forecast period owing to the availability of a large number of drugs for treating HALS and their high efficacy rates. However, cosmetic corrective treatments are also gaining popularity due to their ability to improve appearance and quality of life in patients with HALS. S., Canada, and Mexico.


Global HIV Associated Lipodystrophy Syndrome Treatment Industry Outlook


Product Definition:


HIV Associated Lipodystrophy Syndrome Treatment is the treatment for HIV associated lipodystrophy syndrome. This syndrome is a condition that causes changes in the way a person's body looks. People with this syndrome may have too much fat on their stomach, arms, and legs, or they may lose fat from these areas. They may also have problems with their cholesterol levels and blood sugar levels.


Specific Drug Treatment:


Specific drug treatment, it's usage.


ABSTRACT Introduction of new drugs for the treatment of HIV associated lipodystrophy syndrome is one of the major factors driving growth in this sector. The introduction of novel drugs with different mechanisms of actions has been a major driver for progress over the past few years.


Cosmetic Corrective Treatment:


Cosmetic corrective treatment is a cosmetic procedure that aims to improve the appearance of damaged or disfiguring skin. It includes procedures such as scar revision, acne reduction, and skin tightening. Cosmetic corrective treatments are generally performed by dermatologists but can also be done by certified esthetic professionals under training.


Application Insights:


Based on application, the market is segmented into hospital, specialized clinic and others. Hospital was estimated as the largest revenue generating center in 2017 owing to its wide usage for the treatment of HIV associated lipodystrophy syndrome. It has been observed that patients diagnosed with HIV associated lipodystrophy syndrome are hospitalized due to severe symptoms of weight loss and muscle wasting. This trend is expected to continue over the forecast period due primarily to rising cases of AIDS across various regions coupled with growing awareness about this condition among general practitioners and specialists in clinics worldwide.


HIV-associated lipodystrophy syndrome has been reported most commonly among homosexual males who have sex with men (MSM) globally; however, it can affect people of any sexual orientation or gender identity (GID).


Regional Analysis:


North America dominated the global HIV-associated lipodystrophy syndrome treatment market in 2017. This can be attributed to the presence of key players, availability of effective drugs, high healthcare expenditure and awareness campaigns regarding available treatments for obesity. Moreover, increasing cases of obesity among adults are driving growth in this region. According to CDC statistics published in 2016, more than 30% population aged 20 years and above was obese that year.


Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income leading to improved access to health care facilities along with growing awareness about various treatment options for HIV associated lipodystrophy syndrome & related disorders amongst patients as well as physicians. Furthermore, a large number of patients from China and India have been traveling overseas for medical reasons such as weight loss surgery resulting into an increase in demand for these procedures across this region during the forecast period (2018 - 2030).


Growth Factors:


  • Increasing incidence of HIV-associated lipodystrophy syndrome (HALS)
  • Growing awareness about HALS and its treatment options
  • Rising demand for better and more effective treatments for HALS
  • Availability of government funding for research on HALS treatments
  • Technological advancements in the field of lipodystrophy syndrome treatment

Scope Of The Report

Report Attributes

Report Details

Report Title

HIV Associated Lipodystrophy Syndrome Treatment Market Research Report

By Type

Specific Drug Treatment, Cosmetic Corrective Treatment

By Application

Hospital, Specialist Clinic, Others

By Companies

Gilead Sciences, Amgen, Abbott, AstraZeneca, AbbVie, GlaxoSmithKline, Alfa Wassermann SPA, Theratechnologies, Bristol-Myers Squibb

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

156

Number of Tables & Figures

110

Customization Available

Yes, the report can be customized as per your need.


Global HIV Associated Lipodystrophy Syndrome Treatment Market Report Segments:

The global HIV Associated Lipodystrophy Syndrome Treatment market is segmented on the basis of:

Types

Specific Drug Treatment, Cosmetic Corrective Treatment

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospital, Specialist Clinic, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Gilead Sciences
  2. Amgen
  3. Abbott
  4. AstraZeneca
  5. AbbVie
  6. GlaxoSmithKline
  7. Alfa Wassermann SPA
  8. Theratechnologies
  9. Bristol-Myers Squibb

Global HIV Associated Lipodystrophy Syndrome Treatment Market Overview


Highlights of The HIV Associated Lipodystrophy Syndrome Treatment Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Specific Drug Treatment
    2. Cosmetic Corrective Treatment
  1. By Application:

    1. Hospital
    2. Specialist Clinic
    3. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the HIV Associated Lipodystrophy Syndrome Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global HIV Associated Lipodystrophy Syndrome Treatment Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


There is no specific HIV Associated Lipodystrophy Syndrome treatment, but treatments for the underlying condition are typically effective. Treatment may include medications to improve blood flow and reduce inflammation, weight loss or exercise programs, and surgery to remove fat from areas of excessive accumulation.

Some of the major companies in the hiv associated lipodystrophy syndrome treatment market are Gilead Sciences, Amgen, Abbott, AstraZeneca, AbbVie, GlaxoSmithKline, Alfa Wassermann SPA, Theratechnologies, Bristol-Myers Squibb.

The hiv associated lipodystrophy syndrome treatment market is expected to register a CAGR of 7.5%.

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 HIV Associated Lipodystrophy Syndrome Treatment Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 HIV Associated Lipodystrophy Syndrome Treatment Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 HIV Associated Lipodystrophy Syndrome Treatment Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the HIV Associated Lipodystrophy Syndrome Treatment Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global HIV Associated Lipodystrophy Syndrome Treatment Market Size & Forecast, 2018-2028       4.5.1 HIV Associated Lipodystrophy Syndrome Treatment Market Size and Y-o-Y Growth       4.5.2 HIV Associated Lipodystrophy Syndrome Treatment Market Absolute $ Opportunity

Chapter 5 Global HIV Associated Lipodystrophy Syndrome Treatment Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2 HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Type
      5.2.1 Specific Drug Treatment
      5.2.2 Cosmetic Corrective Treatment
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global HIV Associated Lipodystrophy Syndrome Treatment Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2 HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Applications
      6.2.1 Hospital
      6.2.2 Specialist Clinic
      6.2.3 Others
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global HIV Associated Lipodystrophy Syndrome Treatment Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America HIV Associated Lipodystrophy Syndrome Treatment Analysis and Forecast
   9.1 Introduction
   9.2 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Type
      9.6.1 Specific Drug Treatment
      9.6.2 Cosmetic Corrective Treatment
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Applications
      9.10.1 Hospital
      9.10.2 Specialist Clinic
      9.10.3 Others
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe HIV Associated Lipodystrophy Syndrome Treatment Analysis and Forecast
   10.1 Introduction
   10.2 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Type
      10.6.1 Specific Drug Treatment
      10.6.2 Cosmetic Corrective Treatment
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Applications
      10.10.1 Hospital
      10.10.2 Specialist Clinic
      10.10.3 Others
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific HIV Associated Lipodystrophy Syndrome Treatment Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Type
      11.6.1 Specific Drug Treatment
      11.6.2 Cosmetic Corrective Treatment
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Applications
      11.10.1 Hospital
      11.10.2 Specialist Clinic
      11.10.3 Others
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America HIV Associated Lipodystrophy Syndrome Treatment Analysis and Forecast
   12.1 Introduction
   12.2 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Type
      12.6.1 Specific Drug Treatment
      12.6.2 Cosmetic Corrective Treatment
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Applications
      12.10.1 Hospital
      12.10.2 Specialist Clinic
      12.10.3 Others
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA) HIV Associated Lipodystrophy Syndrome Treatment Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA) HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA) HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Type
      13.6.1 Specific Drug Treatment
      13.6.2 Cosmetic Corrective Treatment
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA) HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Applications
      13.10.1 Hospital
      13.10.2 Specialist Clinic
      13.10.3 Others
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 HIV Associated Lipodystrophy Syndrome Treatment Market: Competitive Dashboard
   14.2 Global HIV Associated Lipodystrophy Syndrome Treatment Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Gilead Sciences
      14.3.2 Amgen
      14.3.3 Abbott
      14.3.4 AstraZeneca
      14.3.5 AbbVie
      14.3.6 GlaxoSmithKline
      14.3.7 Alfa Wassermann SPA
      14.3.8 Theratechnologies
      14.3.9 Bristol-Myers Squibb

Our Trusted Clients

Contact Us